Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 64

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 64
---
ducted a private placement offering (the “First Private Placement Offering”) of units of the Company ’securities,
at the price per unit of $0.80. Each unit (a “Unit” and collectively the “Units”) is comprised of (i) two (2)
shares of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share of the Company’s
Common Stock, exercisable for a 3-year period from the date of the issuance at a per share exercise price of $0.80. We raised aggregate
gross proceeds of $2,790 thousands from the First Private Placement Offering and issued an aggregate of 6,975,000 shares of Common stock
and warrants to purchase 3,562,500 shares of Common Stock to accredited investors in this First Private Placement Offering.

Between April and December 2023, the Company
conducted another private placement of units of its securities at $3.20 price per unit (the “Second Private Placement Offering”),
where each unit (a “Unit” and collectively the “Units”) comprised of (i) two (2) shares of the Common Stock and
(ii) one common stock purchase warrant to purchase an additional share of the Company’s Common Stock exercisable until December
31, 2026, at a per share exercise price of $2.40. In consideration of proceeds in the amount of $4,631.25 thousands received from the
subscribers in the Second Private Placement Offering, we issued to these investors an aggregate of 2,894,532 of the Company’s Common
Stock and warrants to purchase an additional 1,447,266 shares of Common Stock.

The shares of Common Stock sold in the above
offerings and warrants to purchase Common Stock issued by the Company to these investors are included in this registration statement
of which this Prospectus is a part thereof.

Key Financial Terms and Metrics

The following discussion summarizes the key factors
our management believes are necessary for an understanding of our consolidated financial statements.

Revenues

We have not generated any revenues from product
sales to date.

Research and Development Expenses

The process of researching and developing our
product candidates is lengthy, unpredictable and subject to many risks. We expect to continue incurring substantial expenses for the
next several years as we continue to develop our product candidates. We are unable, with any certainty, to estimate either the costs
or the timelines in which those expenses will be incurred. Our current development plans focus on the development of